Here's Why You Should Retain Integer Holdings Stock in Your Portfolio

Integer Holdings Corporation ITGR has been gaining from its research and product development activities. The optimism, led by a solid fourth-quarter 2025 performance and its strength in product sales, is expected to contribute further. However, product-specific headwinds raise concern.

This Zacks Rank #3 (Hold) company’s shares have lost 14.5% over the past six months compared with the industry’s 4.3% fall and the S&P 500’s 0.5% decline.

The renowned medical device outsourcing manufacturer has a market capitalization of $2.97 billion. The company projects 9.1% growth for the next five years and expects to maintain its strong performance going forward. Integer Holdings’ earnings surpassed the Zacks Consensus Estimate in the last reported quarter, delivering a trailing four-quarter average surprise of 2.9%.

Image Source: Zacks Investment Research

Factors Favoring Integer Holdings’ Growth

Strength in Product Sales: Integer Holdings now operates as a single segment focused on medical devices, with product sales driven by its C&V, CRM&N and Other Markets lines. In the fourth quarter of 2025, C&V remained the key growth engine, with sales rising 11% year over year to $284 million (17% growth to $1.1 billion on a trailing basis), supported by acquisitions, new product ramps in electrophysiology and strong neurovascular demand, despite some moderation.

CRM&N declined 2% year over year to $167 million due to weaker demand from certain neuromodulation customers, though annual growth remained modest at 1%, with a stable core CRM business and a pipeline that supports medium-term recovery.

Meanwhile, Other Markets continued to contract due to the planned exit from the Portable Medical business, creating a $30-$35 million headwind expected into 2026, but aligning with the company’s strategy to focus on higher-growth, higher-margin segments.

Research and Product Development: Integer Holdings continues to position R&D as a core growth driver, with its product development engine gaining strong momentum and deepening ties with leading medical device OEMs. Product development sales have risen more than 300% since 2017, with about 80% concentrated in high-growth areas like electrophysiology, neurovascular, structural heart and neuromodulation, reflecting early-stage design involvement that strengthens customer stickiness and future revenue visibility.

The company is currently engaged with around 40 customers across various development phases, particularly in neuromodulation, with a steady pipeline progressing toward commercialization. Revenues from products in the launch and introduction phase have expanded sharply from $10 million in 2018 to about $125 million in 2024 and are expected to grow at a 15-20% CAGR over the next three to five years, supporting management’s confidence in achieving above-market organic growth by 2027.

Alongside this, Integer continues to invest in advanced capabilities such as automation, micro-machining, catheter platforms and rapid prototyping, while expanding its global R&D and manufacturing footprint to sustain long-term innovation.

Solid Q4 Results: Integer Holdings exited the fourth quarter of 2025 with strong results. The strong year-over-year top and bottom-line performances were impressive. Fourth-quarter revenues rose 5% year over year, while adjusted EPS climbed 23%, reflecting solid operating leverage and continued margin expansion. Cardio & Vascular delivered double-digit growth, supported by acquisitions and healthy neurovascular demand, and full-year adjusted operating income increased 13%, underscoring disciplined execution. The company also generated steady free cash flow and reinforced its capital allocation strategy with share repurchases, highlighting confidence in the long-term outlook.

Factor That May Offset ITGR’s Gains

Product-Specific Headwinds Mask Near-Term Growth and Margin Pressure: Integer Holdings is facing near-term headwinds tied to slower-than-expected adoption of three recently launched products, including two in electrophysiology and one in neuromodulation. While these programs were expected to be growth contributors, management now anticipates a 3-4% headwind to 2026 sales, as customer uptake has lagged initial expectations.

Importantly, these products accounted for nearly 6% of 2025 revenues, making the impact meaningful in the near term. The softness is also visible within the CRM&N segment, where fourth-quarter performance was weighed down by weaker demand from select emerging customers, highlighting the inherent variability and lumpiness associated with early-stage product ramps.

Beyond the top-line impact, this demand mismatch is also creating near-term margin pressure, particularly in the first quarter of 2026, where operating margins are expected to decline 200-250 basis points due to lower volume and under-absorption of fixed costs. While management maintains that underlying demand across the core portfolio remains stable and aligned with market growth, these dynamics underscore execution risk around new product commercialization. The situation reinforces that even with a strong pipeline, revenue realization is ultimately dependent on customer adoption timelines, which can introduce volatility and delay the conversion of innovation into financial performance.

Estimate Trend

Integer Holdings is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 7 cents to $6.47 per share.

The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $426.6 million, indicating a 2.5% decline from the year-ago quarter’s reported number. The consensus mark for first-quarter earnings is pegged at $1.21 per share, implying a 7.6% decline from the year-earlier level.

Stocks to Consider

Some better-ranked stocks in the broader medical space that have announced quarterly results are Intuitive Surgical ISRG, Phibro Animal Health PAHC and Cardinal Health CAH.

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.

Phibro Animal Health reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. It currently flaunts a Zacks Rank #1.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

Cardinal Health reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%. It currently carries a Zacks Rank #2 (Buy).

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

Zacks Names #1 Semiconductor Stock

This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.

See This Stock Now for Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Cardinal Health, Inc. (CAH): Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

Integer Holdings Corporation (ITGR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research